Pharmaceutical

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Oct 6, 2024 - 04:00
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Read the original article

Tags:

Previous Article

Can You Lose Weight With Vitamin B12?

Next Article

WuXi debates sale of pharma operations as BIOSECURE Act advances

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: State and local governments across the country are sidelining science

Opinion: State and local governments across the country...

Nov 11, 2023

Bavarian Nordic expands access to mpox vaccine in US

Bavarian Nordic expands access to mpox vaccine in US

Apr 3, 2024

Diabetes ‘epidemic’ gets a Senate hearing

Diabetes ‘epidemic’ gets a Senate hearing

Dec 7, 2023